The search for a cure for persistent HIV reservoirs

AIDS Reviews

Volumn 13, Issue 2, 2011, Pages 63-66

  Lafeuillade, Alain ^a   Stevenson, Mario ^b  

^a GENERAL HOSPITAL   (France)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

HIV cure; HIV eradication; HIV persistence; HIV reservoirs

Indexed keywords

HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN KINASE C; RALTEGRAVIR; VIRUS DNA; VIRUS RNA; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4+ T LYMPHOCYTE; CELL METABOLISM; GENE DELETION; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; MONOCYTE; NONHUMAN; PERSISTENT VIRUS INFECTION; PROTEIN EXPRESSION; RESERVOIR; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE THERAPY; VIRUS GENE; VIRUS LATENCY; VIRUS REPLICATION; ADVISORY COMMITTEE; DISEASE CARRIER; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; PHYSIOLOGY; VIROLOGY;

ADVISORY COMMITTEES; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONALITY; VIRUS LATENCY;

EID: 80053062468     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Choudhary S, Margolis D. Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol. 2011;51:397-418.
2. Richman D, Margolis D, Delaney M, Greene W, Hazuda D, Pomerantz R. The challenge of finding a cure for HIV Infection. Science. 2009; 323:1304-7.
3. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329:174-80.
4. Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7:798-812.
5. Margolis D. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep. 2010;7:37-43.
6. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
7. Josefsson L, Dahl V, Palmer S. Can HIV infection be eradicated through use of potent antiviral agents? Curr Opin Infect Dis. 2010;23:628-32.
8. Onafuwa-Nuga A, McNamara L, Collins K. Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res. 2010;20:1185-7.
9. Chun T, Justement J, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010;24:2803-8.
10. Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood. 2010. [Epub ahead of print].
11. Hütter G, Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS. 2011;25:273-4.
12. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24:1598-601.
13. Shen L, Rabi S, Siliciano R. A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci. 2009;30:610-6.
14. Yukl S, Shergill A, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451-6.
15. Buzón M, Massanella M, Llibre J, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460-5.
16. Nath A, Clements J. Eradication of HIV from the brain: reasons for pause. AIDS. 2011;25:577-80.
17. Lafeuillade A. Translational eradication approaches. Curr Opin HIV/ AIDS. 2006;1:141-6.
18. Imamichi H, Degray G, Asmuth D, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011;25:159-64.
19. Burnett J, Lim K, Calafi A, Rossi J, Schaffer D, Arkin A. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol. 2010;84:5958-74.
20. Savarino A, Mai A, Norelli S, et al. Shock and kill effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthioninesulfoxime in cell line models for HIV-1 quiescence. Retrovirology. 2009;6:52.
21. Engel M, Hiebert S. The enemy within: dormant retroviruses awaken. Nat Med. 2010;16:517-8.
22. Harris K, Brabant W, Styrchak S, Gall A, Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005;67:1-9. (Pubitemid 40798912)
23. Deeks S, McCune J. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010;28:807-10.
24. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28:839-47.